NREP
NEW REPRESENTATIVE AT IB RECEIVED
20/06/2022
Voltar para busca
Dado oficial do USPTO
SYMPHOGEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
SYMPHOGEN
ST13
US500000079075883Classe
1, 5, 42, 45
Pedido
79075883
Registro
3882672
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
58
Atualização mais recente
20/06/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 45
Data de depósito
02/10/2009
Data de registro
30/11/2010
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
02/03/2021
Última transação
02/03/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
DK
Examinador
YARD, JOHN S
Unidade examinadora
M60
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
Symphogen A/S
S. A. (pessoa física)
Representantes
Maury M. Tepper, III Tepper & Eyster, PLLC
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals used in industry, science and photography; biochemicals, namely, human and animal, monoclonal and polyclonal antibodies for in-vivo or in-vitro scientific research and development, including scientific research into diseases, in particular cancer, AIDS (acquired immune deficiency syndrome) and other infectious diseases, immune and auto-immune diseases, inflammatory diseases and cardiovascular diseases
Classe 5
Pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of cancer, AIDS (Acquired Immune Deficiency Syndrome) and other infectious diseases, immune and auto-immune diseases, inflammatory diseases and cardiovascular diseases, Idiopathic Thrombocytopenic Purpura (ITP), Hemolytic Disease of Newborns (HDN), smallpox infection and treatment of adverse effects caused by smallpox vaccination and severe respiratory diseases, hematological diseases, and respiratory diseases; veterinary preparations for cancer, AIDS (Acquired Immune Deficiency Syndrome) and other infectious diseases, immune and auto-immune diseases, inflammatory diseases and cardiovascular diseases, smallpox infection and treatment of adverse effects caused by smallpox vaccination and severe respiratory diseases, and hematological diseases; pharmaceutical preparations based on antibodies, including human, animal, monoclonal and polyclonal antibodies for the treatment of cancer, AIDS (Acquired Immune Deficiency Syndrome) and other infectious diseases, immune and auto-immune diseases, inflammatory diseases and cardiovascular diseases, Indiopathic Thrombocytopenic Purpura (ITP), Hemolytic Disease of Newborns (HDN) smallpox infection and treatment of adverse effects caused by smallpox vaccination and severe respiratory diseases, Hematological diseases and respiratory diseases; dietetic foods adapted for medical use
Classe 42
Research in the field of medical science, including biological research and in particular research into antibodies, including human, animal, monoclonal and polyclonal antibodies and the development of medicines based on antibodies, including human, animal, monoclonal and polyclonal antibodies; chemical analyses; [ computer programming, namely, computer programming for the gathering and processing of medical data in connection with medical science research, development and therapy, including research into, development of, and therapy using antibodies, including human, animal, monoclonal and polyclonal antibodies ]
Classe 45
[ Patent licensing; Patent and industrial property consultation; licensing of industrial property within medical science ]
Publicações
Histórico de despachos e eventos da marca no USPTO.
58 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/06/2022
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
23/04/2022
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
12/03/2022
INPC
INVALIDATION PROCESSED
12/03/2022
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
02/11/2021
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
02/03/2021
71AG
REGISTERED-SEC.71 ACCEPTED
02/03/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/03/2021
ES71
TEAS SECTION 71 RECEIVED
16/11/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
30/10/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
30/10/2020
EWOR
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
30/10/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
30/10/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
30/10/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
30/10/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
23/04/2020
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
30/11/2019
RNWL
INTERNATIONAL REGISTRATION RENEWED
17/10/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/08/2019
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
11/01/2018
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
01/12/2017
INPC
INVALIDATION PROCESSED
01/12/2017
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
15/11/2017
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
15/03/2017
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
15/03/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
15/03/2017
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
09/03/2017
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/03/2017
ES75
TEAS SECTION 71 & 15 RECEIVED
03/10/2016
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
18/02/2013
FICS
FINAL DISPOSITION NOTICE SENT TO IB
31/03/2011
FIMP
FINAL DISPOSITION PROCESSED
31/03/2011
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
28/02/2011
R.PR
REGISTERED-PRINCIPAL REGISTER
30/11/2010
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
14/09/2010
PUBO
PUBLISHED FOR OPPOSITION
14/09/2010
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
12/08/2010
ALIE
ASSIGNED TO LIE
12/08/2010
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/07/2010
XAEC
EXAMINER'S AMENDMENT ENTERED
27/07/2010
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
27/07/2010
GNEA
EXAMINERS AMENDMENT E-MAILED
27/07/2010
CNEA
EXAMINERS AMENDMENT -WRITTEN
27/07/2010
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/07/2010
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/07/2010
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/07/2010
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
30/06/2010
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
30/06/2010
RFNP
REFUSAL PROCESSED BY IB
29/01/2010
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/01/2010
RFRR
REFUSAL PROCESSED BY MPU
05/01/2010
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/01/2010
CNRT
NON-FINAL ACTION WRITTEN
01/01/2010
DOCK
ASSIGNED TO EXAMINER
30/12/2009
MAFR
APPLICATION FILING RECEIPT MAILED
26/12/2009
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/12/2009
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
17/12/2009
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SYMPHOGEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.